Zobrazeno 1 - 10
of 48
pro vyhledávání: ''
Autor:
Kazuya Shinmura, Yuji Iwashita, Masayuki Tanahashi, Kazuhito Funai, Haruhiko Sugimura, Takafumi Suda, Katsuhiro Yoshimura, Naoki Inui, Hiroshi Niwa, Masato Karayama, Hidetaka Yamada, Akikazu Kawase, Yusuke Inoue, Hiroshi Ogawa, Kazuo Tsuchiya
Publikováno v:
Lung Cancer. 141:21-31
Alterations in the MET gene, such as mutations and high-level amplification, are important drivers of non-small cell lung cancer (NSCLC). The efficacy of immune checkpoint inhibitors (ICIs) in lung cancer with MET abnormalities is unclear. We evaluat
Autor:
Anke Behnke, Denise Treue, Philipp Jurmeister, Leonille Schweizer, Maximilian von Laffert, Claudia Vollbrecht, Nikolaj Frost, Jens-Carsten Rückert, David Horst, Jens Neudecker, Frederick Klauschen, Manfred Dietel, Alexander Arnold, Michael Hummel
Publikováno v:
Lung Cancer. 138:43-51
Objectives We aim to provide a better understanding of the molecular landscape of primary lung adenocarcinomas with intestinal differentiation. Material and Methods Five invasive mucinous adenocarcinomas (IMA) and seven pulmonary enteric adenocarcino
Autor:
C. Escriu, John R. Gosney, John K. Field, Michael P.A. Davies, Alexander Haragan, Aaron M Gruver
Publikováno v:
Lung Cancer (Amsterdam, Netherlands)
Lung Cancer
Lung Cancer
Highlights • PD-L1 expression was assessed for heterogeneity in 107 NSCLC patients. • Intra-tumoural heterogeneity was observed in 78% of cases. • Inter-tumoural heterogeneity was observed in 53% of cases. • 23% of cases had clinically releva
Autor:
Thomas Burke, Bilal Piperdi, B. Guldhammer Skov, L. F. Sua, J. Antunez, T. Hida, S. Khambata-Ford, Gilbert Bigras, R. Salanova, A. C. Deitz, Manfred Dietel, Patrick Micke, Hirotoshi Akita, G. Hutarew, N. Savelov, Oscar S.H. Chan
Publikováno v:
Lung Cancer. 134:174-179
Tumor programmed death ligand 1 (PD-L1) expression is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence
Autor:
Simon Ekman, Fred R. Hirsch, Johan Botling, Johanna Sofia Margareta Mattsson, Linnea LaFleur, Georgios Tsakonas, Teresa Boyle, Christopher J. Rivard, Patrick Micke
Publikováno v:
Lung Cancer. 133:69-74
Background c-MET protein overexpression has been proposed as a biomarker in non-small cell lung cancer (NSCLC), albeit its role in the clinical setting has not been firmly established yet. Patients and methods: We designed a retrospective cohort stud
Autor:
Leina Sun, Ming-Sound Tsao, Dongmei Lin, Guangming Tian, Huaiyin Shi, Ziping Wang, Lixin Zhou, Xin Yang, Yaxiong Sang, Haiyue Wang, Ling Jia, Wei Sun, Jian Fang
Publikováno v:
Lung Cancer. 130:135-142
Background High concordance has been observed between Ventana D5F3 ALK immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) in lung adenocarcinoma (LADC). However, whether a similar conclusion can be applied to lung squamous-cell
Autor:
Wendy A Cooper, Stephen Clarke, Tamkin Ahmadzada, Candice Clarke, Glen Reid, Brian C. McCaughan, Anthony Linton, Rebecca Asher, Kenneth Lee, Steven Kao
Publikováno v:
Lung Cancer. 130:35-41
A number of key immune regulators show prognostic value in malignant pleural mesothelioma (MPM), but the association between Bridging integrator 1 (BIN1), indoleamine 2,3 dioxygenase 1 (IDO1) and patient outcome has not been investigated. We aimed to
Publikováno v:
Lung Cancer. 129:41-47
Objectives Therapies that target programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown promising efficacy in non-small-cell lung cancer (NSCLC). Hypoxia-related genes are also important regulators of PD-L1, and the role
Autor:
Hironori Haga, Makoto Sonobe, Akihiro Ohsumi, Terumasa Sowa, Toyofumi F. Chen-Yoshikawa, Yojiro Yutaka, Akihiko Yoshizawa, Shinya Neri, Hiroshi Date, Masatsugu Hamaji, Toshi Menju, Toshihiko Sato, Daisuke Nakajima
Publikováno v:
Lung Cancer. 128:13-19
Microscopic vessel invasion (MVI) and visceral pleural invasion (VPI) have been recently reported as poor prognostic factors of non-small cell lung cancer. Epithelial-mesenchymal transition (EMT) and cancer stemness (CS) are known malignant phenotype
Autor:
Takashi Seto, Kazuki Takada, Mototsugu Shimokawa, Yoshihiko Maehara, Akira Haro, Atsushi Osoegawa, Yoshinao Oda, Tetsuzo Tagawa, Kenichi Kohashi
Publikováno v:
Lung Cancer. 128:26-32
Objectives Combination therapy with an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1) and an agent targeting programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) is expected to be a novel and effective treatment option for variou